Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV) Lessons from past programs and implications for the future

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 6, 2013, Pages 1241-1253

  Holst, Johan ^a   Oster, Philipp ^b   Arnold, Richard ^c   Tatley, Michael V ^d   Næss, Lisbeth M ^a   Aaberge, Ingeborg S ^a   Galloway, Yvonne ^e   McNicholas, Anne ^e   O'Hallahan, Jane ^e   Rosenqvist, Einar ^a   Black, Steven ^f  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b SANOFI PASTEUR   (France)

^c VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^d UNIVERSITY OF OTAGO   (New Zealand)

^e MINISTRY OF HEALTH   (New Zealand)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Controlling MenB epidemics; Meningococcal disease; Neisseria meningitidis; New Zealand MenB Outbreak; OMV vaccines

Indexed keywords

MENINGOCOCCUS VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; BACTERIAL STRAIN; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG FORMULATION; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; EPIDEMIC; HEALTH EDUCATION; IMMUNOGENICITY; IMMUNOREACTIVITY; INFECTION CONTROL; INFORMATION DISSEMINATION; LICENSING; MEMBRANE VESICLE; MENINGOCOCCEMIA; MENINGOCOCCOSIS; MICROBIAL DIVERSITY; NEISSERIA MENINGITIDIS; NEW ZEALAND; OUTER MEMBRANE VESICLE; PUBLIC HEALTH; PUBLIC-PRIVATE PARTNERSHIP; REVIEW; SERUM BACTERICIDAL ACTIVITY; VACCINATION; WILD TYPE;

EID: 84880696347     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.24129     Document Type: Review

References (112)

1. Vieusseux M. Memoire sur le maladie qui a regne a Geneva au printemps de 1805. J Med Clin Pharm 1805; 11:163-82.
2. Danielson L, Mann E. A history of a singular and very noted disease, which lately made its appearance in Medfield. Medical and Agricultural Register 1806; 1:65-9.
3. Weichselbaum A. Ueber die aetiologie der akuten meningitis cerebro-spinal. Fortschr Med 1887; 5:573-83, 620-6.
4. Flexner S. The results of the serum treatment in thirteen hundred cases of epidemic meningits. J Exp Med 1913; 17:553-76; PMID:19867668; http://dx.doi.org/10.1084/jem.17.5.553.
5. Greenwood M. The outbreak of cerebrospinal fever at Salisbury in 1914-15. Proc R Soc Med 1917; 10(Sect Epidemiol State Med):44-60; PMID:19979846.
6. Stephens DS. Uncloaking the meningococcus: dynamics of carriage and disease. Lancet 1999; 353:941-2; PMID:10459897; http://dx.doi.org/10.1016/S0140- 6736(98)00279-7.
7. Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev 2007; 31:3-14; PMID:17233633; http://dx.doi.org/10.1111/j.1574-6976.2006.00051.x.
8. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007; 369:2196-210; PMID:17604802; http://dx.doi.org/10.1016/S0140-6736(07)61016-2.
9. de Souza AL, Seguro AC. Two centuries of meningococcal infection: from Vieusseux to the cellular and molecular basis of disease. J Med Microbiol 2008; 57:1313-21; PMID:18927406; http://dx.doi.org/10.1099/jmm.0.47599-0.
10. Tyler KL. Chapter 28: a history of bacterial meningitis. Handb Clin Neurol 2010; 95:417-33; PMID:19892131; http://dx.doi.org/10.1016/S0072-9752(08) 02128-3.
11. Goldacre MJ, Roberts SE, Yeates D. Case fatality rates for meningococcal disease in an English population, 1963-98: database study. BMJ 2003; 327:596-7; PMID:12969927; http://dx.doi.org/10.1136/bmj.327.7415.596.
12. Sørensen HT, Steffensen FH, Schønheyder HC, Nielsen GL, Hansen I, Madsen KM, et al. Trend in incidence and case fatality of meningococcal disease over 16 years in Northern Denmark. Eur J Clin Microbiol Infect Dis 1998; 17:690-4; PMID:9865981; http://dx.doi.org/10.1007/ s100960050162.
13. Pollard AJ, Frasch C. Development of natural immunity to Neisseria meningitidis. Vaccine 2001; 19:1327-46; PMID:11163654; http://dx.doi.org/10. 1016/S0264-410X(00)00333-9.
14. Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 2004; 23(Suppl):S274-9; PMID:15597069.
15. Gardner P. Clinical practice. Prevention of meningococcal disease. N Engl J Med 2006; 355:1466-73; PMID:17021322; http://dx.doi.org/10.1056/NEJMcp063561.
16. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969; 129:1307-26; PMID:4977280; http://dx.doi.org/10.1084/jem.129.6.1307.
17. Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med 1969; 129:1367-84; PMID:4977283; http://dx.doi.org/10.1084/jem.129.6.1367.
18. Hankins WA, Gwaltney JM Jr., Hendley JO, Farquhar JD, Samuelson JS. Clinical and serological evaluation of a meningococcal polysaccharide vaccine groups A, C, Y, and W135. Proc Soc Exp Biol Med 1982; 169:54-7; PMID:6801667.
19. Griffiss JM, Brandt BL, Altieri PL, Pier GB, Berman SL. Safety and immunogenicity of group Y and group W135 meningococcal capsular polysaccharide vaccines in adults. Infect Immun 1981; 34:725-32; PMID:6800954.
20. Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010; 362:1511-20; PMID:20410516; http://dx.doi.org/10.1056/NEJMra0906357.
21. Lewis S, Sadarangani M, Hoe JC, Pollard AJ. Challenges and progress in the development of a serogroup B meningococcal vaccine. Expert Rev Vaccines 2009; 8:729-45; PMID:19485754; http://dx.doi.org/10.1586/erv.09.30.
22. Gasparini R, Panatto D. Meningococcal glycoconjugate vaccines. Hum Vaccin 2011; 7:170-82; PMID:21178398; http://dx.doi.org/10.4161/hv.7.2.13717.
23. Bröker M, Cooper B, Detora LM, Stoddard JJ. Critical appraisal of a quadrivalent CRM(197) conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo) in the context of treatment and prevention of invasive disease. Infect Drug Resist 2011; 4:137-47; PMID:21904459; http://dx.doi.org/10. 2147/IDR.S12716.
24. Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, Bybel MJ, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 2005; 159:907-13; PMID:16203934; http://dx.doi.org/10.1001/archpedi.159.10.907.
25. Bilukha OO, Rosenstein N; National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005; 54(RR-7):1-21; PMID:15917737.
26. LaForce FM, Okwo-Bele JM. Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine. Health Aff (Millwood) 2011; 30:1049-57; PMID:21653956; http://dx.doi.org/10.1377/hlthaff.2011.0328.
27. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001; 344:1378-88; PMID:11333996; http://dx.doi.org/10.1056/NEJM200105033441807.
28. Wyle FA, Artenstein MS, Brandt BL, Tramont EC, Kasper DL, Altieri PL, et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 1972; 126:514-21; PMID:4197754; http://dx.doi.org/10. 1093/infdis/126.5.514.
29. Bruge J, Bouveret-Le Cam N, Danve B, Rougon G, Schulz D. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine 2004; 22:1087-96; PMID:15003635; http://dx.doi.org/10.1016/j.vaccine.2003.10.005.
30. Granoff DM. Review of meningococcal group B vaccines. Clin Infect Dis 2010; 50(Suppl 2):S54-65; PMID:20144017; http://dx.doi.org/10.1086/648966.
31. Sadarangani M, Pollard AJ. Serogroup B meningococcal vaccines-an unfinished story. Lancet Infect Dis 2010; 10:112-24; PMID:20113980; http://dx.doi.org/10.1016/S1473-3099(09)70324-X.
32. Holst J, Martin D, Arnold R, Huergo CC, Oster P, O'Hallahan J, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009; 27(Suppl 2):B3-12; PMID:19481313; http://dx.doi.org/10.1016/j.vaccine. 2009.04.071.
33. Holst J, Feiring B, Naess LM, Norheim G, Kristiansen P, Høiby EA, et al. The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 2005; 23:2202-5; PMID:15755595; http://dx.doi.org/10.1016/j.vaccine. 2005.01.058.
34. Taha MK, Zarantonelli ML, Alonso JM, Naess LM, Holst J, Feiring B, et al. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks. Vaccine 2007; 25:2537-8; PMID:16460845; http://dx.doi.org/10.1016/j.vaccine. 2005.12.059.
35. Helting TB, Guthöhrlein G, Blackkolb F, Ronneberger H. Serotype determinant protein of Neisseria Meningitidis. Large scale preparation by direct detergent treatment of the bacterial cells. Acta Pathol Microbiol Scand C 1981; 89:69-78; PMID:6794337.
36. Tsai CM, Frasch CE, Mocca LF. Five structural classes of major outer membrane proteins in Neisseria meningitidis. J Bacteriol 1981; 146:69-78; PMID:6783622.
37. Frasch CE. Meningococcal Vaccines: Past, Present and Future. In: Cartwright K, editor. Meningococcal Disease. New York: John Wiley & Sons, 1995: 245-83.
38. Frasch C, Van Alphen L, Holst J, Poolman J, Rosenqvist E. Outer membrane protein vesicle vaccines for meningococcal disease. In: Pollard AJ, Maiden MC, editors. Meningococcal vaccines: methods and protocols. Totowa, New Jersey: Humana Press, 2001: 81-107.
39. Zollinger WD, Boslego J, Frøholm LO, Ray JS, Moran EE, Brandt BL. Human bactericidal antibody response to meningococcal outer membrane protein vaccines. Antonie Van Leeuwenhoek 1987; 53:403-11; PMID:3130779; http://dx.doi.org/10.1007/BF00415494.
40. Zollinger WD, Mandrell RE, Altieri P, Berman S, Lowenthal J, Artenstein MS. Safety and immunogenicity of a Neisseria meningitidis type 2 protein vaccine in animals and humans. J Infect Dis 1978; 137:728-39; PMID:77885; http://dx.doi.org/10.1093/infdis/137.6.728.
41. Frasch CE, Robbins JD. Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model. J Exp Med 1978; 147:629-44; PMID:416164; http://dx.doi.org/10. 1084/jem.147.3.629.
42. Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, Sotolongo PF, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991; 14:195-207, discussion 208-10; PMID:1812432.
43. Bjune G, Høiby EA, Grønnesby JK, Arnesen O, Fredriksen JH, Halstensen A, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991; 338:1093-6; PMID:1682541; http://dx.doi.org/10.1016/0140-6736(91)91961-S.
44. Holst J, Feiring B, Fuglesang JE, Høiby EA, Nøkleby H, Aaberge IS, et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003; 21:734-7; PMID:12531351; http://dx.doi.org/ 10.1016/S0264-410X(02)00591-1.
45. Rosenqvist E, Høiby EA, Wedege E, Bryn K, Kolberg J, Klem A, et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 1995; 63:4642-52; PMID:7591118.
46. Feiring B, Fuglesang J, Oster P, Naess LM, Helland OS, Tilman S, et al. Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine. Clin Vaccine Immunol 2006; 13:790-6; PMID:16829617; http://dx.doi.org/10.1128/CVI.00047-06.
47. Perkins BA, Jonsdottir K, Briem H, Griffiths E, Plikaytis BD, Høiby EA, et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis 1998; 177:683-91; PMID:9498448; http://dx.doi.org/10.1086/514232.
48. Tappero JW, Lagos R, Ballesteros AM, Plikaytis B, Williams D, Dykes J, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999; 281:1520-7; PMID:10227322; http://dx.doi.org/10.1001/jama.281.16.1520.
49. Wenger JD. Serogroup B meningococcal disease: new outbreaks, new strategies. JAMA 1999; 281:1541-3; PMID:10227326; http://dx.doi.org/10.1001/ jama.281.16.1541.
50. Martin DR, Walker SJ, Baker MG, Lennon DR. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J Infect Dis 1998; 177:497-500; PMID:9466547; http://dx.doi.org/10.1086/517385.
51. O'Hallahan J, Lennon D, Oster P, Lane R, Reid S, Mulholland K, et al. From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease. Vaccine 2005; 23:2197-201; PMID:15755594; http://dx.doi.org/10.1016/j.vaccine.2005.01.061.
52. O'Hallahan J, Martin D, Oster P. An epidemic of group B meningococcal of disease controlled by a vaccine-the final chapter. 15th International Pathogenic Neisseria Conference; 2006 September 10-15, 2006; Cairns, Australia; 2006. p. 42.
53. Loring BJ, Turner N, Petousis-Harris H. MeNZB vaccine and epidemic control: when do you stop vaccinating? Vaccine 2008; 26:5899-904; PMID:18804134; http://dx.doi.org/10.1016/j.vaccine.2008.08.062.
54. Holst J, Aaberge IS, Oster P, Lennon D, Martin D, O'Hallahan J, et al. A "tailor made" vaccine trialled as part of public health response to group B meningococcal epidemic in New Zealand. Euro Surveill 2003; 7:pii=2262.
55. Martin DR, Ruijne N, McCallum L, O'Hallahan J, Oster P. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol 2006; 13:486-91; PMID:16603616; http://dx.doi.org/10.1128/CVI. 13.4.486-491.2006.
56. Thornton V, Lennon D, Rasanathan K, O'Hallahan J, Oster P, Stewart J, et al. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine 2006; 24:1395-400; PMID:16242221; http://dx.doi.org/10.1016/j.vaccine.2005.09.043.
57. Galloway Y, Stehr-Green P, McNicholas A, O'Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol 2009; 38:413-8; PMID:18988650; http://dx.doi.org/10.1093/ije/dyn228.
58. Jackson C, Lennon DR, Sotutu VT, Yan J, Stewart JM, Reid S, et al. Phase II meningococcal B vesicle vaccine trial in New Zealand infants. Arch Dis Child 2009; 94:745-51; PMID:18838420; http://dx.doi.org/10.1136/adc.2007.132571.
59. Tyson J, Norman R. Fighting a Fearful Disease; Controlling New Zealand's meningococcal B epidemic. Institute of Policy Studies, Victoria University of Wellington, The Australian and New Zealand School of Government 2007.
60. Claassen I, Meylis J, van der Ley P, Peeters C, Brons H, Robert J, et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 1996; 14:1001-8; PMID:8873395; http://dx.doi.org/10.1016/0264-410X(96)00020-5.
61. Cartwright K, Morris R, Rümke H, Fox A, Borrow R, Begg N, et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 1999; 17:2612-9; PMID:10418910; http://dx.doi.org/10.1016/S0264-410X(99)00044-4.
62. Holst J. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them. Hum Vaccin 2007; 3:290-4; PMID:17712231.
63. Fredriksen JH, Rosenqvist E, Wedege E, Bryn K, Bjune G, Frøholm LO, et al. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann 1991; 14:67-79, discussion 79-80; PMID:1812438.
64. Bjaering Hansen N, Høiby EA, Caugant DA, Frøholm LO, Holst J, Tangen T, et al. Development and evaluation of experimental meningococcal B:4:P1.(7),4 outer membrane vaccines. In: Nassif X, Quentin-Millet MJ, Taha MK, editors. 11th International Pathogenic Neisseria Conference; 1998 November 1-6, 1998; Nice, France: Editions E.D.K.; 1998. p. 169.
65. Rosenqvist E, Bryn K, Harbak K, Holst J, Høiby EA, Kristiansen P, et al. Development of a tailor-made outer membrane vesicle vaccine against the group B meningococcal epidemic in New Zealand. In: Caugant DA, Wedege E, editors 13th International Pathogenic Neisseria Conference; September 1-6, 2002 Oslo: Nordberg Aksidenstrykkeri AS; 2002 p64 2002.
66. Lennon D, Jackson C, Wong S, Horsfall M, Stewart J, Reid S. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. Clin Infect Dis 2009; 49:597-605; PMID:19622040; http://dx.doi.org/10.1086/603552.
67. Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005; 23:2191-6; PMID:15755593; http://dx.doi.org/10.1016/j.vaccine.2005.01.063.
68. Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. Immunogenicity and safety of a strainspecific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine 2007; 25:3075-9; PMID:17289223; http://dx.doi.org/10.1016/j.vaccine. 2007.01.023.
69. Wong S, Lennon D, Jackson C, Stewart J, Reid S, Crengle S, et al. New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months. Pediatr Infect Dis J 2007; 26:345-50; PMID:17414400; http://dx.doi.org/10.1097/01.inf.0000258697.05341.2c.
70. Balmer P, Borrow R. Serologic correlates of protection for evaluating the response to meningococcal vaccines. Expert Rev Vaccines 2004; 3:77-87; PMID:14761245; http://dx.doi.org/10.1586/14760584.3.1.77.
71. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 2005; 23:2222-7; PMID:15755600; http://dx.doi.org/10.1016/j.vaccine.2005.01.051.
72. Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D, et al. Neisseria meningitidis group B correlates of protection and assay standardization-international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 2006; 24:5093-107; PMID:16838413; http://dx.doi.org/10.1016/j.vaccine.2006.03.091.
73. Martin D, McCallum L, Glennie A, Ruijne N, Blatchford P, O'Hallahan J, et al. Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials. Vaccine 2005; 23:2218-21; PMID:15755599; http://dx.doi.org/10.1016/j.vaccine. 2005.01.070.
74. Borrow R, Aaberge IS, Santos GF, Eudey TL, Oster P, Glennie A, et al. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin Diagn Lab Immunol 2005; 12:970-6; PMID:16085915.
75. Kelly C, Arnold R, Galloway Y, O'Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol 2007; 166:817-23; PMID:17615088; http://dx.doi.org/10.1093/aje/kwm147.
76. Arnold R, Galloway Y, McNicholas A, O'Hallahan J. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine 2011; 29:7100-6; PMID:21803101; http://dx.doi.org/10.1016/j.vaccine.2011.06. 120.
77. Wong SH, Lennon DR, Jackson CM, Stewart JM, Reid S, Ypma E, et al. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine. Pediatr Infect Dis J 2009; 28:385-90; PMID:19384263; http://dx.doi.org/10.1097/INF.0b013e318195205e.
78. O'Hallahan J, Lennon D, Oster P. The strategy to control New Zealand's epidemic of group B meningococcal disease. Pediatr Infect Dis J 2004; 23(Suppl):S293-8; PMID:15597072.
79. Tatley MV, Kunac DL, McNicholas A, Zhou L, Ballantyne S, Ashton J, et al. The Intensive Vaccines Monitoring Programme (IVMP): an electronic system to monitor vaccine safety in New Zealand. Vaccine 2008; 26:2746-52; PMID:18430496; http://dx.doi.org/10.1016/j.vaccine.2008.03.017.
80. McNicholas A, Galloway Y, Stehr-Green P, Reid S, Radke S, Sexton K, et al. Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006. Hum Vaccin 2007; 3:196-204; PMID:17660718; http://dx.doi.org/10.4161/hv.3.5.4458.
81. Holst J, Nøkleby H, Bettinger JA. Considerations for controlling invasive meningococcal disease in high income countries. Vaccine 2012; 30(Suppl 2):B57-62; PMID:22607900; http://dx.doi.org/10.1016/j.vaccine.2011.12.093.
82. O'Hallahan J, McNicholas A, Galloway Y, O'Leary E, Roseveare C. Delivering a safe and effective strainspecific vaccine to control an epidemic of group B meningococcal disease. N Z Med J 2009; 122:48-59; PMID:19322255.
83. Sexton K, McNicholas A, Galloway Y, Radke S, Kieft C, Stehr-Green P, et al. Henoch-Schönlein purpura and meningococcal B vaccination. Arch Dis Child 2009; 94:224-6; PMID:18650242; http://dx.doi.org/10.1136/adc.2007.125195.
84. Stehr-Green P, Radke S, Kieft C, Galloway Y, McNicholas A, Reid S. The risk of simple febrile seizures after immunisation with a new group B meningococcal vaccine, New Zealand. Vaccine 2008; 26:739-42; PMID:18187240; http://dx.doi.org/10.1016/j.vaccine. 2007.12.001.
85. Stehr-Green P, Galloway Y, Kieft C, McNicholas A. The risk of bronchiolitis hospitalisation following administration of a group B meningococcal vaccine in New Zealand. N Z Med J 2007; 120:U2746; PMID:17972966.
86. Nøkleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine 2007; 25:3080-4; PMID:17287053; http://dx.doi.org/10.1016/j.vaccine. 2007.01.022.
87. Sexton K, Lennon D, Oster P, Crengle S, Martin D, Mulholland K, et al. The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic. N Z Med J 2004; 117:U1015; PMID:15475985.
88. McNicholas A, Galloway Y, Martin D, Sexton K, O'Hallahan J. Surveillance of vaccine breakthrough cases following MeNZB vaccination. N Z Med J 2008; 121:38-46; PMID:18425153.
89. Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A 2010; 107:19490-5; PMID:20962280; http://dx.doi.org/10.1073/pnas.1013758107.
90. Wedege E, Høiby EA, Rosenqvist E, Bjune G. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Infect Immun 1998; 66:3223-31; PMID:9632589.
91. Martin D, Lopez L, Sexton K. The epidemiology of meningococcal disease in New Zealand in 2006. Report from Institute of Environmental Science and Research Ltd, Wellington 2007.
92. Sotolongo FP, Campa C, Casanueva VG, Fajardo EM, Cuevas IE, González N. Cuban meningococcal BC Vaccine: experiences and contributions from 20 years of application. MEDICC Rev 2007; 9:16-22; PMID:21487356.
93. Giuliani MM, Adu-Bobie J, Comanducci M, Aricò B, Savino S, Santini L, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 2006; 103:10834-9; PMID:16825336; http://dx.doi.org/10.1073/pnas. 0603940103.
94. Bai X, Findlow J, Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther 2011; 11:969-85; PMID:21615224; http://dx.doi.org/10.15 17/14712598.2011.585965.
95. Su EL, Snape MD. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease. Expert Rev Vaccines 2011; 10:575-88; PMID:21604979; http://dx.doi.org/10.1586/erv.11.32.
96. Pizza M, DeTora L, Wassil J. Advances in meningococcal vaccines. Clin Pract 2012; 9:101-17; http://dx.doi.org/10.2217/cpr.11.128.
97. Bai XF, Findlow J, Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther 2011; 11:969-85; PMID:21615224; http://dx.doi.org/10.15 17/14712598.2011.585965.
98. Sow SO, Okoko BJ, Diallo A, Viviani S, Borrow R, Carlone G, et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011; 364:2293-304; PMID:21675889; http://dx.doi.org/10.1056/ NEJMoa1003812.
99. Bambini S, Muzzi A, Olcen P, Rappuoli R, Pizza M, Comanducci M. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 2009; 27:2794-803; PMID:19428890; http://dx.doi.org/10.1016/j.vaccine.2009.02. 098.
100. Jansen KU, McNeil LK, Dragalin V, Anderson AS, Hoiseth SK, Arora A, et al. Bivalent recombinant LP2086 vaccine to provide broad protection against Neisseria meningitidis B disease: Immunological correlates of protection and how to assess coverage against invasive MnB strains. In: van Alphen L, van Ley P, van den Dobbelsteen G, editors. 16th International Pathogenic Neisseria Conference. Rotterdam, The Netherlands, 2008: abstract 064.
101. Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, Fink PS, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009; 200:379-89; PMID:19534597; .
102. Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010; 28:6086-93; PMID:20619376; http://dx.doi.org/10.1016/j.vaccine.2010.06.083.
103. Lennon D, Reid S, Stewart J, Jackson C, Crengle S, Percival T. Reducing inequalities with vaccines: New Zealand's MeNZB vaccine initiative to control an epidemic. J Paediatr Child Health 2012; 48:193-201; PMID:21996021; http://dx.doi.org/10.1111/j.1440-1754.2010.01969.x.
104. Caron F, du Châtelet IP, Leroy JP, Ruckly C, Blanchard M, Bohic N, et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis 2011; 11:455-63; PMID:21489881; http://dx.doi.org/10.1016/S1473-3099(11)70027-5.
105. Caron F, Delbos V, Houivet E, Deghmane AE, Leroy JP, Hong E, et al. Evolution of immune response against Neisseria meningitidis B:14:P1.7,16 before and after the outer membrane vesicle vaccine MenBvac. Vaccine 2012; 30:5059-62; PMID:22658929; http://dx.doi.org/10.1016/j.vaccine.2012.05.051.
106. Koeberling O, Seubert A, Granoff DM. Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. J Infect Dis 2008; 198:262-70; PMID:18505380; http://dx.doi.org/10.1086/589308.
107. Pajon R, Fergus AM, Koeberling O, Caugant DA, Granoff DM. Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development. PLoS Negl Trop Dis 2011; 5:e1302; PMID:21909444; http://dx.doi.org/10.1371/journal.pntd.0001302.
108. Fisseha M, Chen P, Brandt B, Kijek T, Moran E, Zollinger W. Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination. Infect Immun 2005; 73:4070-80; PMID:15972495; http://dx.doi.org/10.1128/IAI.73.7.4070-4080.2005.
109. Keiser PB, Biggs-Cicatelli S, Moran EE, Schmiel DH, Pinto VB, Burden RE, et al. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 2011; 29:1413-20; PMID:21199704; http://dx.doi.org/10.1016/j.vaccine.2010.12.039.
110. Zollinger WD, Babcock JG, Moran EE, Brandt BL, Matyas GR, Wassef NM, et al. Phase I study of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide. Vaccine 2012; 30:712-21; PMID:22138211; http://dx.doi.org/10.1016/j.vaccine.2011.11.084.
111. Moran EE, Burden R, Labrie JE 3rd, Wen Z, Wang XM, Zollinger WD, et al. Analysis of the bactericidal response to an experimental Neisseria meningitidis vesicle vaccine. Clin Vaccine Immunol 2012; 19:659-65; PMID:22461527; http://dx.doi.org/10.1128/CVI.00070-12.
112. van der Ley P, van den Dobbelsteen G. Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants. Hum Vaccin 2011; 7:886-90; PMID:21785281; http://dx.doi.org/10.4161/hv.7.8. 16086.